M. Vigliotti

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer

Melissa L. Johnson, P. Janne, Dong-Wan Kim, 2021, Cancer discovery.

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).

P. Jänne, Melissa L. Johnson, Dong-Wan Kim, 2021 .

Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis.

R. Lucito, D. Levine, N. Dimitrova, 2013, Gynecologic oncology.

Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC.

P. Jänne, Melissa L. Johnson, Channing Yu, 2019, Journal of Clinical Oncology.

Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study.

H. Iwata, K. Yonemori, N. Masuda, 2018 .

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)

A. DeCillis, C. Zwaan, E. Kolb, 2019, Blood.

Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis.

R. Lucito, D. Levine, N. Dimitrova, 2013, Gynecologic oncology.